We then investigated whether varlitinib modulates neuroinflammation and AD pathology in a mouse model of AD and found that varlitinib downregulated neuroinflammatory responses, tau hyperphosphorylation, and tau kinase DYRK1A expression in 3-month-old tau-overexpressing PS19 mice and, to a lesser extent, in 6-month-old tau-overexpressing PS19 mice (Figure 11). The gene discussed is MAPT; the disease is Alzheimer disease.